Cerus (NasdaqGM:CERS) Q4 2025 Earnings call March 02, 2026 04:30 PM ET Company ParticipantsKevin Green - CFOTim Lee - Head of Investor RelationsVivek Jayaraman - COOWilliam Greenman - President and CEOConference Call ParticipantsBill Bonello - Senior Research AnalystMark Massaro - Managing Director and Senior Equity Research AnalystOperatorGood day, ladies and gentlemen. Thank you for standing by. Welcome to the Cerus Corporation fourth quarter and full year 2025 earnings conference call. Please be advised ...

Financial Data and Key Metrics Changes - Total revenues for 2025 reached $233.8 million, a record level for the company, representing a 16% increase from 2024 [16] - Product revenue increased by 14% for both the fourth quarter and the full year, exceeding prior guidance of $202 million-$204 million [16] - Product gross margin for Q4 was 51.5%, down from 53.9% in the same period last year, impacted by higher production costs and inflationary pressures [20][21] - GAAP net loss for Q4 was $2.2 million, with a full-year loss of $15.6 million, down 25% from the prior year [24] Business Line Data and Key Metrics Changes - The U.S. platelet franchise is estimated to hold a market share in the mid-60s, with strong growth expected due to a new group purchasing agreement with the Blood Centers of America [10][11] - IFC product revenue grew by nearly 40% in Q4 compared to the same period last year, with a full-year growth of approximately 80% [18] - EMEA product revenue increased by 25% in Q4 and 14% for the full year, driven by strong demand in both platelet and plasma franchises [17] Market Data and Key Metrics Changes - The INITIATE study in Germany represents a $30 million annual platelet opportunity, with enrollment starting in January 2026 [12][41] - Demand for IFC increased by over 50% in Q4 compared to the same period last year, indicating strong market traction [13] - The company estimates that IFC market adoption exited 2025 at around 7%, with expectations to increase penetration significantly by the end of 2026 [19] Company Strategy and Development Direction - The company aims to establish the INTERCEPT Blood System as the global standard of care for transfused blood components, with ongoing investments in innovation and regulatory approvals [6][7] - The recent launch of the INT200 device is seen as a foundational element for global growth, with positive customer feedback reinforcing the company's leadership in transfusion medicine [7] - The strategic partnership with the Blood Centers of America is expected to enhance market penetration and facilitate broader discussions across the network [11][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued revenue growth into 2026, reaffirming product revenue guidance of $224 million-$228 million, representing a year-over-year increase of 9%-11% [19] - The company anticipates a third consecutive year of positive adjusted EBITDA, driven by revenue growth and disciplined expense management [25] - Management acknowledged ongoing inflationary pressures and import tariffs as potential challenges to gross margins in 2026 [21] Other Important Information - The company ended 2025 with nearly $83 million in cash and short-term investments, maintaining prudent cash management while funding growth initiatives [25] - Operating cash flow for the full year was $4.8 million, consistent with expectations despite increased investments [26] Q&A Session Summary Question: Can you elaborate on the BCA agreement and its impact on blood centers? - Management highlighted that the BCA agreement allows leveraging their supply chain and contracting platforms, which is expected to drive penetration in the U.S. platelet market [30][31] Question: What are the expectations for cash flow in 2026? - Management indicated that cash flow generation is expected to continue, with ongoing investments in inventory to support anticipated growth [34][35] Question: Can you provide an update on the INITIATE study in Germany? - The INITIATE study is expected to lead to increased revenue contributions starting in 2027, with the market opportunity estimated at $30 million annually [41][42] Question: What is the status of red blood cells in Europe? - The regulatory submission for red blood cells is under review, with potential approval expected in the first half of 2027 [44] Question: What is the growth potential in the Middle East? - Management noted significant opportunities in Saudi Arabia and other countries, with INTERCEPT platelets being influenced by U.S. standards [48][49]

Financial Data and Key Metrics Changes - For Q3 2025, the company reported record product revenue of $52.7 million, a 15% year-over-year increase [20] - Year-to-date product revenue for the first nine months of 2025 reached $148.4 million, also reflecting a 15% increase compared to the same period in 2024 [20] - Product gross profit for Q3 was $28.1 million, a 7% increase from $26.2 million in the prior year, while product gross margins decreased to 53.4% from 56.9% due to inflationary pressures and higher production costs [25][26] Business Line Data and Key Metrics Changes - The Intercept platelet franchise remains the foundation of the business, with US market penetration estimated at mid-60%, up from low 60% a year ago [6] - IFC sales in Q3 were $3.9 million, a significant increase from $2.3 million in Q3 2024, with a year-over-year revenue increase of approximately 70% and volume demand up about 110% [22][24] - The shift from direct sales to hospitals to IFC kit sales to blood centers is expected to continue, with approximately 70% of dose-equivalent unit sales tied to kits in Q3 compared to less than 25% the previous year [15][24] Market Data and Key Metrics Changes - AMEA product revenues increased by 21% year-over-year, driven by strong Middle Eastern platelet sales and initial shipments to Germany [21] - North American product revenues increased by 11% year-over-year, led by gains in the United States [21] Company Strategy and Development Direction - The company aims to establish a complete portfolio of pathogen-inactivated blood components worldwide, with ongoing regulatory reviews and clinical trials [32] - The transition to a kit-based model for IFC sales is designed to leverage existing blood center sales channels and reduce contract cycle times, enhancing market access [42][43] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued momentum across franchises, raising the full-year 2025 product revenue guidance to $202-$204 million [24][31] - The company anticipates a strong finish to 2025, with expectations for record revenue in Q4 and positive growth projections for 2026 [19][31] Other Important Information - The company achieved its sixth consecutive quarter of positive non-GAAP adjusted EBITDA, totaling $5 million for Q3 2025 [28] - Cash generated from operations during Q3 was $1.9 million, with a stable cash balance of $78.5 million at the end of the quarter [28][30] Q&A Session Summary Question: What are the expectations for gross margin headwinds in 2026? - Management indicated that some headwinds, such as foreign exchange rates and tariffs, are out of their control, but they can focus on growing the business and improving product mix to drive margin expansion [35] Question: How will the company meet growing demand for IFC? - Management stated that production and supply capabilities have improved significantly, and they do not foresee supply constraints in the near future [36] Question: What drove the decision to shift towards a kit-based model for IFC? - The shift was primarily driven by the ability to leverage existing blood center sales channels and contracts, which reduces cycle time and improves gross margins [41][42]